Trabectedin and Durvalumab Combination Is Feasible and Active in Relapsing Ovarian Cancer.
Détails
ID Serval
serval:BIB_0CAC463D4200
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Editorial
Collection
Publications
Institution
Titre
Trabectedin and Durvalumab Combination Is Feasible and Active in Relapsing Ovarian Cancer.
Périodique
Clinical cancer research
ISSN
1557-3265 (Electronic)
ISSN-L
1078-0432
Statut éditorial
Publié
Date de publication
02/05/2022
Peer-reviewed
Oui
Volume
28
Numéro
9
Pages
1745-1747
Langue
anglais
Notes
Publication types: Editorial ; Comment
Publication Status: ppublish
Publication Status: ppublish
Résumé
The combination of chemotherapy and immune therapies still promises to synergize for prolonged tumor control. However, the quest for optimal combinations tailored for tumor histology remains ongoing. A recent study provides evidence on the feasibility of the trabectedin/durvalumab combination and reports on interesting preliminary efficacy. See related article by Toulmonde et al., p. 1765.
Mots-clé
Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Carcinoma, Ovarian Epithelial/drug therapy, Dioxoles/adverse effects, Female, Humans, Neoplasm Recurrence, Local/drug therapy, Ovarian Neoplasms/drug therapy, Ovarian Neoplasms/pathology, Sarcoma/drug therapy, Soft Tissue Neoplasms/drug therapy, Tetrahydroisoquinolines/adverse effects, Trabectedin
Pubmed
Web of science
Création de la notice
01/03/2022 12:38
Dernière modification de la notice
15/07/2022 6:36
Données d'usage
